BiotechTube
Omnio

Omnio

Stockholm, Sweden· Est.
omnio.se
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Funding information not available

Overview

Omnio is a private, preclinical-stage biotech developing a novel recombinant plasminogen therapy for chronic wounds, starting with diabetic foot ulcers. The company's approach aims to address the underlying biological failure in chronic wounds by clearing damaged tissue, fighting infection, and promoting skin regeneration via a simple subcutaneous injection. With GMP manufacturing and clinical trial applications planned for 2026-2027, Omnio is positioning itself to address a multi-billion euro market with high unmet need.

Wound HealingDiabetic Foot Ulcers

Technology Platform

Recombinant production of human plasminogen (Rec-PLG) for therapeutic application. The protein is designed to restart the stalled natural healing cascade in chronic wounds by performing multiple functions: debridement of damaged tissue, fighting infection (including antibiotic-resistant bacteria), and promoting skin regeneration.

Opportunities

The global chronic wound market represents a multi-billion euro burden with high unmet need, especially for diabetic foot ulcers where current treatments often fail, leading to amputations.
Omnio's regenerative approach, if clinically validated, could capture significant market share by offering improved healing rates, reduced amputations, and lower long-term healthcare costs compared to palliative standard of care.

Risk Factors

Key risks include clinical trial failure, as the complex pathophysiology of chronic wounds has led to many past failures; regulatory hurdles for a novel biologic; competition from other advanced wound care therapies; and execution risks in manufacturing and trial initiation.
As a pre-revenue private company, securing ongoing financing is also a critical risk.

Competitive Landscape

Omnio competes in the advanced wound care market, which includes advanced dressings, negative pressure wound therapy, skin substitutes (e.g., amniotic membranes), and growth factor therapies (e.g., Regranex). Its differentiation lies in its multi-functional, endogenous protein approach targeting the root cause of stalled healing, contrasting with single-mechanism or palliative options. It will face competition from both large medtech companies and other biotechs developing novel biologics.

More companies in Sweden →